Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally?The Motley Fool • 10/19/26
5 Dividend Stocks for Investors Who Want Income Without the Market's Wild Swings24/7 Wall Street • 10/19/26
Pfizer's Non-Oncology Performance in Q3: Driving Factors to WatchZacks Investment Research • 10/19/26
These 5 Dividend Stocks Look Like Income Bargains. The Math Says Otherwise24/7 Wall Street • 10/19/26
Here's What $10,000 in Each of These 5 High-Yield Dividend Stocks Could Pay You in a YearThe Motley Fool • 10/18/26
Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?The Motley Fool • 10/16/26
Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady24/7 Wall Street • 10/16/26
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put24/7 Wall Street • 10/16/26
Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher24/7 Wall Street • 10/15/26
Forget Treasury Bonds: This 6%-Yielding Pharma Stock Pays You to Wait for Its PipelineThe Motley Fool • 10/14/26
5 Large-Cap Giants Paying 5% and Bigger Dividends to Be Bought and Held Forever24/7 Wall Street • 10/14/26
Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026Business Wire • 10/14/26
Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industryWSJ • 10/13/26
Johnson & Johnson Drops 5% as One-Time Charges Overshadow Raised Full-Year Outlook; Eli Lilly Dips, Pfizer Sits Out the Selloff24/7 Wall Street • 10/13/26
FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma banBusiness Insider • 10/13/26
These 6 Dividend Stocks Look Like Income Bargains. Their Payout Ratios Say Otherwise24/7 Wall Street • 10/13/26
Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small MoleculesBusiness Wire • 10/13/26
Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 10/12/26
Pfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock?Zacks Investment Research • 10/12/26